Prudentia Sciences, a Cambridge, MA-based provider of an AI-powered technology platform for life sciences, raised $7M in funding.
The round was led by GV, with participation from Iaso Ventures and Virtue.
The company intends to use the funds to accelerate its pace of product development and deployment, enhancing its AI-native due diligence platform and expanding its capabilities.
Led by CEO Sadiqa Mahmood, CTO John Reynders, Prudentia Sciences is a technology company dedicated to accelerating drug pipelines and optimizing return on investment, ensuring healthcare innovations reach their clinical development milestones, patient impact and full commercial potential. The platform combines artificial intelligence with deep scientific expertise and advanced financial modeling to address the complex challenges of life sciences dealmaking. It offers rapid asset diligence and valuation capability incorporating clinical development, regulatory and reimbursement considerations. The system empowers biopharma companies and investors to identify critical risks, accelerate go/no-go decisions, and optimize trade-offs swiftly across key dimensions such as time, cost, probability of success, and revenue.
